Class summary at a glance.

Every drug in the Atypical Antipsychotic class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 18tracked in Part D
CY24 Part D spend: $6.60Bcombined across class
Total Rx claims: 39.9M7.1M unique beneficiaries
Generic mfrs (active): 137across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Cariprazine

Brand: Vraylar · 1.2M Part D claims (CY24) · 216K beneficiaries · First FDA approval: 2015-09-17

Brand-only (no generics) 308 plans require PA

Low NADAC$50.91

→

Avg plan cost$50.95

Part D spend $1.75B 1× spread, current vs floor

Class share

27%

of class CY24 spend

View profile →

Aripiprazole

Brand: ABILIFY · 6.2M Part D claims (CY24) · 1.3M beneficiaries · First FDA approval: 2002-11-15

22 generic mfrs 1127 plans require PA

Low NADAC$0.098

→

Avg plan cost$62.47

Part D spend $1.45B 639× spread, current vs floor

Class share

22%

of class CY24 spend

View profile →

Brexpiprazole

Brand: Rexulti · 972K Part D claims (CY24) · 179K beneficiaries · First FDA approval: 2015-07-10

1 generic mfrs 750 plans require PA

Low NADAC$49.50

→

Avg plan cost$49.60

Part D spend $1.37B 1× spread, current vs floor

Class share

21%

of class CY24 spend

View profile →

Lumateperone

Brand: CAPLYTA · 253K Part D claims (CY24) · 50K beneficiaries · First FDA approval: 2020-02-01

Brand-only (no generics) 330 plans require PA

Low NADAC$57.33

→

Avg plan cost$57.36

Part D spend $425.1M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Quetiapine

Brand: Quetiapine Fumarate · 14.8M Part D claims (CY24) · 2.7M beneficiaries · First FDA approval: 1997-10-01

16 generic mfrs 794 plans require PA

Low NADAC$0.029

→

Avg plan cost$0.749

Part D spend $315.0M 26× spread, current vs floor

Class share

of class CY24 spend

View profile →

Lurasidone

Brand: Latuda · 1.3M Part D claims (CY24) · 224K beneficiaries · First FDA approval: 2010-10-28

16 generic mfrs 250 plans require PA

Low NADAC$0.143

→

Avg plan cost$3.08

Part D spend $284.5M 22× spread, current vs floor

Class share

of class CY24 spend

View profile →

Risperidone

Brand: PERSERIS · 5.7M Part D claims (CY24) · 904K beneficiaries · First FDA approval: 1993-12-29

25 generic mfrs 611 plans require PA

Low NADAC$0.036

→

Avg plan cost$460.75

Part D spend $283.1M 12781× spread, current vs floor

Class share

of class CY24 spend

View profile →

Olanzapine

Brand: ZYPREXA · 6.0M Part D claims (CY24) · 1.1M beneficiaries · First FDA approval: 1996-10-01

25 generic mfrs 521 plans require PA

Low NADAC$0.080

→

Avg plan cost$2.26

Part D spend $193.0M 28× spread, current vs floor

Class share

of class CY24 spend

View profile →

Clozapine

Brand: Clozaril · 1.8M Part D claims (CY24) · 134K beneficiaries · First FDA approval: 1999-07-08

5 generic mfrs 940 plans require PA

Low NADAC$0.263

→

Avg plan cost$4.61

Part D spend $161.9M 18× spread, current vs floor

Class share

of class CY24 spend

View profile →

Iloperidone

Brand: FANAPT · 65K Part D claims (CY24) · 8K beneficiaries · First FDA approval: 2015-09-15

Brand-only (no generics) 1592 plans require PA

Low NADAC$30.46

→

Avg plan cost$41.04

Part D spend $132.9M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Paliperidone

Brand: INVEGA · 602K Part D claims (CY24) · 96K beneficiaries · First FDA approval: 2006-12-19

11 generic mfrs 653 plans require PA

Low NADAC$0.978

→

Avg plan cost$642.14

Part D spend $119.1M 657× spread, current vs floor

Class share

of class CY24 spend

View profile →

Ziprasidone

Brand: Geodon · 942K Part D claims (CY24) · 146K beneficiaries · First FDA approval: 2003-12-23

10 generic mfrs 60 plans require PA

Low NADAC$0.270

→

Avg plan cost$2.84

Part D spend $69.1M 10× spread, current vs floor

Class share

of class CY24 spend

View profile →

Asenapine

Brand: Asenapine · 114K Part D claims (CY24) · 21K beneficiaries · First FDA approval: 2013-09-30

3 generic mfrs 597 plans require PA

Low NADAC$2.23

→

Avg plan cost$12.80

Part D spend $44.6M 6× spread, current vs floor

Class share

of class CY24 spend

View profile →

Aripiprazole Oral

Brand: Aripiprazole · — Part D claims (CY24) · First FDA approval: 2023-11-01

Brand-only (no generics)

Low NADAC$0.320

→

Avg plan cost$0.320

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Aripiprazole Orally Disintegrating

Brand: Aripiprazole · — Part D claims (CY24) · First FDA approval: 2018-04-18

Brand-only (no generics) 80 plans require PA

Low NADAC$2.87

→

Avg plan cost$3.30

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Olanzapine and Fluoxetine

— Part D claims (CY24) · First FDA approval: 2012-06-19

3 generic mfrs

Low NADAC$3.76

→

Avg plan cost$5.48

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Olanzapine and Fuoxetine

Brand: Olanzapine and Fluoxetine · — Part D claims (CY24) · First FDA approval: 2012-11-26

Brand-only (no generics) 10 plans require PA

Low NADAC$3.76

→

Avg plan cost$5.48

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Olanzapine and Samidorphan L-Malate

Brand: LYBALVI · — Part D claims (CY24) · First FDA approval: 2021-09-20

Brand-only (no generics) 404 plans require PA

Low NADAC$55.03

→

Avg plan cost$55.10

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.